The risks identified through Clinical Evaluation have been compared to the residual risks identified in the EPIQ Affiniti QLAB 9.0 Risk Management Matrix (Section {MQ}5.6.1{MQ}) and warnings/precautions included in product labeling ({MQ}Appendix 1{MQ} and {MQ}Appendix 2{MQ}).Safety-related IFU content includes information for safety communicated to the user in order to avoid harm (risk mitigation measures), and information communicated to the user in order to inform the user about the unavoidable risks involved when using the device (disclosed residual risks).